» Articles » PMID: 36241962

Real-World Analysis of Treatment Patterns, Healthcare Utilization, Costs, and Mortality Among People with Biliary Tract Cancers in the USA

Overview
Journal Adv Ther
Date 2022 Oct 14
PMID 36241962
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: People with advanced biliary tract cancers (BTCs) have a 5-year survival of approximately 2% in the USA. Most cases are inoperable or require systemic treatment following surgery. This study adds to current literature by describing treatment patterns, healthcare resource utilization (HCRU), costs, and mortality among people with BTCs.

Methods: Adults diagnosed with BTCs were identified in the Merative MarketScan administrative claims databases from 1 January 2016 to 30 June 2020. Descriptive analysis was used to measure treatment patterns (i.e., regimen types, therapy duration) during three lines of therapy (LOT). All-cause and disease-related HCRU and costs were measured per-patient-per-month (PPPM) during the entire follow-up and in each LOT. Mortality was reported among the subset linked to the National Death Index (NDI).

Results: There were 2648 eligible people with BTCs [mean age 64.0 (standard deviation [SD] 12.4) years, 51.5% female, average follow-up 11.9 (SD 11.1) months]. Treatment was received by 56.3% (n = 1490), and 20.9% (n = 5534) and 7.1% (n = 187) moved on to a second and third LOT, respectively. The average treatment duration decreased across LOTs, from 3.8 (SD 3.1) months in LOT1 to 2.6 (SD 2.4) months in LOT3. Gemcitabine + cisplatin was the most common regimen in LOT1 (44.6%). Total all-cause mean healthcare costs PPPM increased after LOT1 (mean $21,517, $29,721, and $28,557, for LOT1, LOT2, and LOT3, respectively) and the majority (71.2%) were related to BTCs. Of people with BTCs linked to the NDI (n = 2168), 66.1% died and average time to death was 11.3 (SD 11.2) months.

Conclusions: These findings, showing a high rate of mortality, a decrease in treatment duration, and an increase in costs as people progress after LOT1, add recent data to current literature highlighting the unmet need for more effective treatment options for people with BTCs.

Citing Articles

Treatment Patterns and Outcomes in Patients with Advanced Biliary Tract Cancers Treated with Gemcitabine-Based Chemotherapy: A Retrospective Study.

Dayyani F, Stirnadel-Farrant H, Hu J, Lin Y, Kebede N, Valerio S Cancers (Basel). 2025; 17(2.

PMID: 39858087 PMC: 11764298. DOI: 10.3390/cancers17020305.


Real-world treatment patterns, resource utilization and costs in biliary tract cancers in the USA.

Wang L, Singhal M, Valderrama A, Nepal B, Kamble S, Eluri M Future Oncol. 2024; 20(34):2625-2636.

PMID: 39155836 PMC: 11534106. DOI: 10.1080/14796694.2024.2379237.


The Global Burden of Early-Onset Biliary Tract Cancer: Insight From the Global Burden of Disease Study 2019.

Danpanichkul P, Ng C, Tan D, Muthiah M, Kongarin S, Srisurapanont K J Clin Exp Hepatol. 2024; 14(2):101320.

PMID: 38261906 PMC: 10796968. DOI: 10.1016/j.jceh.2023.101320.

References
1.
Banales J, Marin J, Lamarca A, Rodrigues P, Khan S, Roberts L . Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020; 17(9):557-588. PMC: 7447603. DOI: 10.1038/s41575-020-0310-z. View

2.
Patel N, Benipal B . Incidence of Cholangiocarcinoma in the USA from 2001 to 2015: A US Cancer Statistics Analysis of 50 States. Cureus. 2019; 11(1):e3962. PMC: 6436669. DOI: 10.7759/cureus.3962. View

3.
Wadhwa V, Jobanputra Y, Thota P, Menon K, Parsi M, Sanaka M . Healthcare utilization and costs associated with cholangiocarcinoma. Gastroenterol Rep (Oxf). 2016; 5(3):213-218. PMC: 5554388. DOI: 10.1093/gastro/gow026. View

4.
Oh D, He A, Qin S, Chen L, Okusaka T, Vogel A . Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2024; 1(8):EVIDoa2200015. DOI: 10.1056/EVIDoa2200015. View

5.
Raderer M, Hejna M, Valencak J, Kornek G, Weinlander G, Bareck E . Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology. 1999; 56(3):177-80. DOI: 10.1159/000011961. View